6 terminated, 5 completed, 1 withdrawn. 12 Phase 1, 8 Phase 2.
By phase and status
Follow Idasanutlin: new trials by email Literature Review of Idasanutlin trials Research Report on Idasanutlin
Trials (filtered) newest first · largest first
All 12 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors Idasanutlin, Selinexor - Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Withdrawn | | 2024-03-01 | 2024-03-27 |
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors Idasanutlin, Venetoclax, Cyclophosphamide - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 1 / Phase 2 | Terminated | 38 | 2020-01-27 | 2024-12-20 |
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission Idasanutlin, Cytarabine, Daunorubicin - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | 24 | 2019-03-25 | 2022-06-21 |
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) Regorafenib, Atezolizumab, Imprime PGG - Colorectal Cancer | Phase 1 / Phase 2 | Terminated | 96 | 2018-09-27 | 2023-11-07 |
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer Atezolizumab, Cobimetinib, Idasanutlin - Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 1 / Phase 2 | Terminated | 12 | 2018-07-10 | 2021-08-11 |
NCT Neuro Master Match - N²M² (NOA-20) APG101, Alectinib, Idasanutlin - Glioblastoma, Adult | Phase 1 / Phase 2 | Completed | 228 | 2018-05-07 | 2023-09-28 |
A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors Idasanutlin - Solid Tumors | Phase 1 | Completed | 48 | 2017-11-27 | 2019-06-19 |
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL) Idasanutlin, Obinutuzumab, Venetoclax - Follicular Lymphoma, Lymphoma, Large B-Cell, Diffuse | Phase 1 / Phase 2 | Terminated | 29 | 2017-06-15 | 2021-12-07 |
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies) Idasanutlin, Placebo, [13C]-radiolabeled Idasanutlin - Solid Tumors | Phase 1 | Completed | 8 | 2016-09-08 | 2017-12-18 |
A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy Cobimetinib, Idasanutlin, Venetoclax - Leukemia, Myeloid, Acute | Phase 1 | Completed | 88 | 2016-03-09 | 2022-01-03 |
Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Dexamethasone, Idasanutlin, Ixazomib Citrate - Loss of Chromosome 17p, Recurrent Plasma Cell Myeloma | Phase 1 / Phase 2 | Completed | 33 | 2015-12-30 | 2024-09-19 |
A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants Idasanutlin, Obinutuzumab, Rituximab - Non-Hodgkin's Lymphoma | Phase 1 / Phase 2 | Terminated | 25 | 2015-12-23 | 2020-05-18 |
Conditions studied
Leukemia, Myeloid, Acute (3) · Breast Neoplasms (1) · Central Nervous System Neoplasms (1) · Chromosome 17 deletion (1) · Colorectal Neoplasms (1) · Glioblastoma (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Neuroblastoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Rhabdoid Tumor (1)
Sponsors
Hoffmann-La Roche (8) · Mayo Clinic (1) · St. Jude Children's Research Hospital (1) · University Hospital Heidelberg (1) · Vanderbilt-Ingram Cancer Center (1)
Countries
United States (9) · Australia (4) · France (4) · Canada (3) · Germany (3) · South Korea (3) · Italy (2) · New Zealand (2) · Spain (2) · Hungary (1) · Netherlands (1) · Switzerland (1) · United Kingdom (1)
Top investigators
Amar Gajjar, MD (1) · Ingrid Mayer, MD (1) · Shaji Kumar, M.D. (1) · Wolfgang Wick, Prof. Dr. (1)
Results publications
PMID 36265087, PMID 40913172, PMID 41379293
NIH funding
2015 (4), 2018 (2), 2016 (1), 2017 (1)